NCT05564650View on ClinicalTrials.gov

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

April 10, 2026

Study Completion Date

April 10, 2026

Conditions
Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome
Interventions
BIOLOGICAL

Navitoclax

Given PO

DRUG

Venetoclax

Given PO

DRUG

Decitabine

Given IV

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Thomas Jefferson University

OTHER